Delivery Order SPE2DB24D2018-SPE2DB24FWRL1
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $1,504.80, is for the delivery of pharmaceutical products, including the drug ZEPBOUND 5 MG/0.5 ML PEN 0.5ML. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of March 13, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of pharmaceutical products and medical supplies. The award, valued at $15,164.66, is a Firm Fixed Price delivery order contract with a completion date of January 19, 2024. The contract covers the procurement of a specific medical product, "ZEPBOUND 7.5 MG/0.5 ML PEN 0.5ML," with no set-aside designation. Amerisourcebergen Drug Corp...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $4,475.14 under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of pharmaceutical products, including the drug ZEPBOUND, to support military healthcare programs. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp has established itself as...
- This federal contract award, valued at $5,197.05, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of pharmaceutical products, including the medication ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to provide a...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order (SPE2DB24FU02H) valued at $18,297.44 for the supply of the pharmaceutical product "ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML." The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of May 7, 2024. The contract is for a firm fixed price with no set-aside designation, indicating full and open competition. Amerisourcebergen...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $6,360.80 delivery order is for the medical product "ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML" and has a period of performance through February 27, 2024. The contract is a firm fixed price delivery order, indicating the government procured a specific quantity of the product at a pre-determined price. This award is not associated with a set-aside...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $2,707.60 firm fixed-price delivery order is for the medical product "ZEPBOUND 15 MG/0.5 ML PEN 0.5ML" and has a completion date of February 9, 2024. The contract has no set-aside designation, indicating it was competitively awarded. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at $4,378.16, is a Firm Fixed Price Delivery Order for the supply of the pharmaceutical product "ZEPBOUND 2.5 MG/0.5 ML PEN 0.5ML". The ultimate completion date for this award is December 27, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,143.87 Firm Fixed Price Delivery Order contract covers the provision of the pharmaceutical product "ZEPBOUND 10 MG/0.5 ML PEN 0.5ML" with a performance period through March 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $23,008.35 firm fixed-price delivery order is for the supply of the pharmaceutical product "ZEPBOUND 5 MG/0.5 ML PEN 0.5ML". The contract has an ultimate completion date of April 3, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- SPE2DB24D2018Indefinite Delivery Contract
- SPE2DB24D2018-SPE2DB24FWRL1Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The award, valued at $2,344.91, is for the delivery of pharmaceutical products, including the drug ZEPBOUND 5 MG/0.5 ML PEN 0.5ML. This is a delivery order contract with a firm fixed price pricing type, and the ultimate completion date is February 12, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Additionally, Cencora, Inc. maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs demonstrate Amerisourcebergen's capacity to meet the diverse and critical pharmaceutical needs of multiple government agencies on a large scale. The contract award does not have a set-aside designation, indicating open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 2/9/24 |